ENGOT-Cx6/GEICO 73-C (A González)
A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.
ENGOT-CX1/GEICO 43-O (MJ Rubio)
Phase II study, of treatment every 3 weeks with carboplatin (AUC 5) + 175 mg/m2 of paclitaxel, with or without concomitant nintedanib and maintenance, in advanced or recurrent cervical carcinoma.
GEICO 61-C/AIM2CERV (A Oaknin)
Phase 3 of ADX11-001 administered following chemoradiation as adjuvant treatment for HRLACC.
GEICO 46-O/CECILIA (A Redondo)
Phase II carbo-paclitaxel-bevacizumab in the first line of persistent, recurrent or disseminated cervical carcinoma.
Phase III randomized trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the doublet without platinum, Topotecan plus Paclitaxel, with and without Bevacizumab, in recurrent or persistent stage IVB cervical carcinoma.
Phase II exploratory study to evaluate the efficacy and safety of weekly topotecan in the treatment of persistent or relapsing cervical cancer after failure of first-line treatment with platinum derivatives.